PUBLISHER: Current Partnering | PRODUCT CODE: 271128
PUBLISHER: Current Partnering | PRODUCT CODE: 271128
Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of cancer diagnostic deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 755 cancer diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading cancer diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
Cancer Diagnostic Collaboration and Licensing Deals includes:
Analyzing contract agreements allows due diligence of:
Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits: